Abstract
PurposeThe purpose of this study was to retrospectively evaluate the quantitative and qualitative intrapatient concordance of pulmonary nodule risk assessment by commercially available radiomics software between full-dose (FD) chest-CT and ultra-low-dose (ULD) chest CT. Materials and methodsBetween July 2013 and September 2015, 68 patients (52 men and16 women; mean age, 65.5±10.6 [SD] years; range: 35–87 years) with lung nodules≥5mm and<30mm who underwent the same day FD chest CT (helical acquisition; 120kV; automated tube current modulation) and ULD chest CT (helical acquisition; 135kV; 10mA fixed) were retrospectively included. Each nodule on each acquisition was assessed by a commercial radiomics software providing a similarity malignancy index (mSI), classifying it as “benign-like” (mSI<0.1); “malignant-like” (mSI>0.9) or “undetermined” (0.1≤mSI≤0.9). Intrapatient qualitative agreement was evaluated with weighted Cohen–Kappa test and quantitative agreement with intraclass correlation coefficient (ICC). ResultsNinety-nine lung nodules with a mean size of 9.14±4.3 (SD) mm (range: 5–25mm) in 68 patients (mean 1.46 nodule per patient; range: 1–5) were assessed; mean mSI was 0.429±0.331 (SD) (range: 0.001–1) with FD chest CT (22/99 [22%] “benign-like”, 67/99 [68%] “undetermined” and 10/99 [10%] “malignant-like”) and mean mSI was 0.487±0.344 (SD) (range: 0.002–1) with ULD chest CT (20/99 [20%] “benign-like”, 59/99 [60%] “undetermined” and 20/99 [20%] “malignant-like”). Qualitative and quantitative agreement of FD chest CT with ULD chest CT were “good” with Kappa value of 0.60 (95% CI: 0.46–0.74) and ICC of 0.82 (95% CI: 0.73–0.87), respectively. ConclusionA good agreement in malignancy similarity index can be obtained between ULD chest CT and FD chest CT using radiomics software. However, further studies must be done with more case material to confirm our results and elucidate the diagnostic capabilities of radiomics software using ULD chest CT for lung nodule characterization by comparison with FD chest CT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.